Using the COMPASS model, researchers project risk of cardiac late effects for survivors of pediatric ALL at age 50 years.

Researchers sought to determine whether the ALL-Hematotox would be able to predict hematotoxicity for patients with B-ALL who are at risk of severe hematotoxicity following CAR-T therapy.

Adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) face significant survival disparities and ...

Pharmaceutical Co. Ltd.’s LYN/BTK dual inhibitor, DZD-8586, saw tumor shrinkage in 94.1% of patients with relapsed or ...

Kura Oncology won FDA priority review for its drug the day before announcing new data at ASCO 2025 showing remission in about ...

An international clinical trial led by WashU Medicine researchers shows an innovative CAR-T cell immunotherapy is promising ...

Allogeneic CAR-T cell therapy is produced using CRISPR gene editing from cells donated by healthy individuals.

A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, according to the results ...

DelveInsight’s Natural Killer (NK)-Cell Lymphoma Pipeline report depicts a robust space with 100+ active players working to develop 140+ pipeline therapies for Natural Killer (NK)-Cell Lymphoma ...

TEVIMBRA is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is ...

In recent years, the therapeutic landscape for hematological malignancies has undergone a profound transformation, driven by the development and regulatory ...

A night of body slams, fun, and community support is coming to St. Thomas Aquinas Academy on Friday, May 23rd, as Under The Lights Entertainment presents ...